In the bustling heart of New York City, a prestigious event is set to take place on November 7, 2024, at the American Museum of Natural History. This event, known as the Prix Galien USA Awards Ceremony, is a beacon of recognition for groundbreaking achievements in the life sciences. Organized by The Galien Foundation, this annual ceremony honors the tireless efforts of researchers, scientists, and innovators who have made significant contributions to healthcare and human well-being.

The Galien Foundation: A Legacy of Excellence

The Galien Foundation, named after Galen, the father of medical science and modern pharmacology, has a rich history of fostering and rewarding excellence in scientific innovation. Established in 1970 by Roland Mehl, the foundation's mission is to improve human health by recognizing and promoting innovative treatments and technologies. The foundation's vision is to be a catalyst for the development of the next generation of medical advancements that will save lives and transform medical practice.

The foundation oversees the Prix Galien, an international awards program with chapters in 14 countries, including a newly established chapter in India in 2024. The Prix Galien is often regarded as the equivalent of the Nobel Prize in biopharmaceutical research, highlighting its significance in the scientific community.

The 2024 Prix Galien USA Awards

This year, the Prix Galien USA Awards Committee, composed of 11 renowned leaders from the biomedical industry and academia, including three Nobel Laureates, has announced the nominees for three prestigious categories: "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases." These nominees represent the pinnacle of scientific achievement and innovation in their respective fields.

▍Best Biotechnology Product Nominees

The nominees for the "Best Biotechnology Product" category include a diverse array of groundbreaking treatments and therapies. Among them are:

    TEZSPIRE® by Amgen and AstraZeneca

    ZORYVE® by Arcutis Biotherapeutics, Inc.

    VYVGART® by argenx

    Beyfortus® by AstraZeneca and Sanofi

    Brukinsa® by BeiGene

    ENHERTU® by Daiichi Sankyo & AstraZeneca

    EPKINLY® by Genmab and AbbVie

    AREXVY by GSK

    XACDURO® by Innoviva Specialty Therapeutics, Inc.

    Bylvay® by Ipsen

    Rylaze® by Jazz Pharmaceuticals

    TALVEY™ by Johnson & Johnson

    TECVAYLI™ by Johnson & Johnson

    CARVYKTI® by Johnson & Johnson and Legend Biotech

    CAPVAXIVE™ by Merck & Co Inc.

    DNBSEQ-T20 by MGI Tech

    PREVNAR 20® by Pfizer Inc.

    ABRYSVO® by Pfizer Inc.

    Dupixent® by Regeneron and Sanofi

    PreHevbrio™ by VBI Vaccines Inc.

    XPS with STEEN Solution by XVIVO Perfusion

These products showcase the incredible advancements in biotechnology, offering new hope and improved outcomes for patients worldwide.

▍Best Pharmaceutical Product Nominees

The "Best Pharmaceutical Product" category features nominees that have demonstrated exceptional potential to improve human health. The nominees include:

    ELAHERE® by AbbVie

    LYBALVI® by Alkermes, Inc.

    XPHOZAH® by Ardelyx, Inc.

    LUPKYNIS® by Aurinia Pharmaceuticals Inc.

    ZURZUVAE® by Biogen Inc. and Sage Therapeutics

    LEQEMBI® by Eisai and Biogen Inc.

    Kisunla™ by Eli Lilly and Company

    Ocrevus® by Genentech, A Member of the Roche Group

    PHESGO® by Genentech, A Member of the Roche Group

    VABYSMO™ by Genentech, A Member of the Roche Group

    Sunlenca® by Gilead Sciences

    iDose® TR by Glaukos Corporation

    Opzelura® by Incyte

    JORNAY PM® by Ironshore

    RYBREVANT® by Johnson & Johnson

    WINREVAIR™ by Merck & Co. Inc.

    LIVMARLI® (maralixibat) oral solution by Mirum Pharmaceuticals, Inc.

    PLUVICTO® by Novartis

    CIBINQO® by Pfizer Inc.

    PAXLOVID™ by Pfizer Inc.

    VOQUEZNA® (vonoprazan) by Phathom Pharmaceuticals

    Tzield® by Sanofi

    TIBSOVO® by Servier Pharmaceuticals

    Myfembree® by Sumitomo Pharma America, Inc.

    Apretude (cabotegravir extended-release injectable suspension) by ViiV Healthcare

These pharmaceutical products represent the forefront of medical innovation, addressing a wide range of health conditions and improving the quality of life for countless individuals.

▍Best Product for Rare/Orphan Diseases Nominees

The "Best Product for Rare/Orphan Diseases" category highlights treatments that address rare and often overlooked medical conditions. The nominees include:

    WAINUA™ by AstraZeneca and Ionis Pharmaceuticals

    SKYCLARYS® by Biogen Inc.    

    QALSODY® by Biogen Inc. and Ionis Pharmaceuticals

    KIMMTRAK® by Immunocore    

    ZTALMY® by Marinus Pharmaceuticals, Inc.

    Evkeeza® by Regeneron

    Xenpozyme® by Sanofi

    OGSIVEO® by SpringWorks Therapeutics

These products are a testament to the dedication and ingenuity of researchers and scientists who strive to make a difference in the lives of patients with rare diseases.

A Celebration of Innovation and Dedication

The Prix Galien USA Awards Ceremony is more than just an event; it is a celebration of the relentless pursuit of excellence in the life sciences. As Bruno Cohen, Chairman of The Galien Foundation, aptly stated, "Each year, we have the honor of convening in New York City to celebrate the groundbreaking achievements that are improving health and longevity for all." This event serves as a reminder of the invaluable contributions made by those who work tirelessly to advance healthcare and inspire excellence within the industry.

As we look forward to the 2024 Prix Galien USA Awards Ceremony, we celebrate the remarkable achievements of this year's nominees. Their dedication, innovation, and unwavering commitment to improving human health are truly inspiring. Through their efforts, we move closer to a future where innovative treatments and technologies transform lives and bring hope to patients around the world.

Source  Prix Galien USA (galienfoundation.org)